Wright G Paul, Wong Jan H, Morgan John W, Roy-Chowdhury Sharmila, Kazanjian Kevork, Lum Sharon S
Department of Surgery, Division of Surgical Oncology, Loma Linda University School of Medicine, Loma Linda, California 92350, USA.
Am Surg. 2010 Oct;76(10):1119-22.
No clear guidelines exist defining the appropriate time frame from diagnosis to definitive surgical treatment of breast cancer. Studies have suggested that treatment delays greater than 90 days may be associated with stage migration. We sought to evaluate demographic factors that influence 30-day and 90-day benchmarks for time from diagnosis to definitive surgical treatment of breast cancer. Between 2004 and 2007, 19,896 women with stage I to III invasive breast cancer were treated with primary surgical therapy and did not receive preoperative systemic therapy in the California Cancer Registry. Overall, 75.7 per cent of patients were treated within 30 days of diagnosis, and 95.5 per cent of patients were treated within 90 days of diagnosis. Multivariate analyses revealed that treatment delays were associated with smaller tumor size, use of total mastectomy, lower socioeconomic status, and Hispanic and nonHispanic black race/ethnicity. Furthermore, disparities in those that did not meet 30-day benchmark timeframes were exaggerated with 90-day treatment delays. These benchmarks can be used to measure disparities in health care delivery.
目前尚无明确的指南来界定乳腺癌从诊断到确定性手术治疗的合适时间框架。研究表明,治疗延迟超过90天可能与分期进展有关。我们试图评估影响乳腺癌从诊断到确定性手术治疗的30天和90天基准时间的人口统计学因素。在2004年至2007年期间,加利福尼亚癌症登记处有19896例I至III期浸润性乳腺癌女性接受了原发性手术治疗,且未接受术前全身治疗。总体而言,75.7%的患者在诊断后30天内接受了治疗,95.5%的患者在诊断后90天内接受了治疗。多变量分析显示,治疗延迟与肿瘤较小、采用全乳切除术、社会经济地位较低以及西班牙裔和非西班牙裔黑人种族/族裔有关。此外,未达到30天基准时间框架的患者之间的差异在90天治疗延迟时被放大。这些基准可用于衡量医疗服务提供方面的差异。